BIAF Stock Surges 85%, Breaks 200-DMA For The First Time In Nearly A Year – Here’s What’s Driving The Rally

• CyPath Lung uses AI to analyze cells in sputum samples, helping identify potential cancer signals without invasive procedures.
• The company’s non-invasive test kit was successfully used on a 71-year-old former smoker with multiple lung nodules.
• The company expects CyPath Lung test sales to more than double in 2026 on the back of an 87% jump in full-year 2025.

BioAffinity Technologies (BIAF) stock soared about 85% on Monday, breaking above its 200-day moving average for the first time since April 2025, as a sharp rally pushed the stock up more than 160% over the past week.

Source: TradingView

Meanwhile, retail sentiment on Stocktwits remained in the ‘bullish’ territory over the past 24 hours amid ‘extremely high’ message volumes.

What Did Stocktwits Users Say?

One user expects the stock to climb past $10 after hours. It is currently trading near $5.

Another user highlighted the company’s international patents and added that the stock is worth double its current value.

BioAffinity’s CyPath Lung Test Shows Promise in Real-World Case

Last week, BioAffinity reported encouraging results from a case study of its CyPath Lung test, a non-invasive tool designed to assess lung cancer risk. The test was used on a 71-year-old former smoker with multiple lung nodules and indicated the condition was likely due to inflammation rather than cancer, later confirmed by follow-up scans.

CyPath Lung uses artificial intelligence to analyze cells in sputum samples, helping identify potential cancer signals without invasive procedures. The update adds to growing momentum for the test, which has become the company’s primary focus.

CyPath Lung Sales Expected To More Than Double In 2026

On March 13, 2026, BioAffinity shares surged 98% after the company reported an 87% jump in full-year 2025 CyPath Lung revenue to $963,000.

However, the company’s total revenue declined to $6.2 million from $9.4 million as it exited non-core services to focus on its flagship test, while net loss widened to $14.9 million due to higher development and sales costs.

BioAffinity also raised $16.9 million to fund growth, expecting CyPath Lung sales to more than double in 2026. Meanwhile, it is advancing research in COPD and asthma diagnostics, with patient studies planned this year.

Year-to-date, the stock has gained more than 300%.

Read also: NVDA Stock Rebounds But Remains Below Key Support For Second Session: Retail Sees Massive Upside

For updates and corrections, email newsroom[at]stocktwits[dot]com.